NTLA

#1996
Intellia Therapeutics, Inc. - Common Stock
13.9 4 USD
+1.90%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
13.71
14.00
년간 변동
0.12
17.09
일일 변동
+1.90%
월간 변동
+10.46%
6달 변화
+58.23%
년간 변동율
+1.60%
이전 종가
13.6 8
Open
13.7 6
저가
13.7 1
High
14.0 0
양
997
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 1.95 B
  • Employee 377
  • Founded 2014
  • CEO John Leonard
  • Website www.intelliatx.com
  • Headquarter Delaware, United States
  • FIGI BBG007KC7PB0
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-2.36
주가매출액비율
14.4

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

뉴스